Re:US appeals court rules in favor of patenting genes
by rayiner on Friday August 24, 2012 @01:10AM
(#4426313)
My opinion is that the decision is correct: isolated genes are patentable subject matter. I think the Myriad patent should fail on novelty: they isolated a bunch of variations on the BRCA genes that were indicative of cancer. These variations are naturally occurring and indeed common. Just as you can't patent the chemical composition of sulfuric acid, because it's common in nature and thus not novel, you shouldn't be able to patent these variations.
Re:US appeals court rules in favor of patenting genes
by zmmmmm on Friday August 24, 2012 @02:03AM
(#4426441)
If I understand it right, the basis for the "novelty" is not the mutations, rather it is that they are testing cDNA (effectively, a gene with exons spliced out, but as DNA not RNA - so this never exists in nature as such, because splicing occurs on the RNA transcript).
My problem with it is that the so called "novel" molecule is a result of a process that is not inventive - it is a systematic process that is routinely done all the time, and which is entirely based on and constrained by the natural enzymes that perform it. So I don't see why a molecule that is merely a mechanical result of a non-novel process is novel.
What I find hard to understand is that if Myriad has patented but one transformation of the DNA (and this being part of the justification for why it is patentable), then surely there must be many other transformations that enable the same test to be carried out, and people should be freely and easily working around this. But they don't seem to be; it seems through patenting one specific transformation Myriad have secured a monopoly on any kind of testing of the gene. I don't understand how they are having their cake and eating it too here.